We are celebrating this week as Nexelis has been recognized at the Vaccine Industry Excellence (ViE) awards, in Washington DC.
The ViE awards were created to honor and recognize the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry. Nexelis was presented with the Best Central/Specialty Laboratory Award at an exclusive awards dinner ceremony that was held in conjunction with the 22nd World Vaccine Congress Washington.
“This prestigious award is yet another recognition of the work that Nexelis continues to deliver for our partners who develop vaccines for many of the world’s most dangerous and difficult to prevent diseases. As a world leader in advanced laboratory testing for vaccine development and leading specialty laboratory with best-in-class capabilities in assay and biomarker development, advanced bioanalytical testing and translational immunology we continue to raise the bar and deliver excellence.” – Luc Gagnon, Vice President of Vaccine Sciences and Laval, Canada Site Head
Nexelis is proud to have won the award for two years in a row, as the vaccine industry has been under intense pressure and scrutiny to bring new advances quickly to market due to the COVID-19 pandemic. Nexelis plays an integral role in the fight against SARS-CoV-2, partnering with multiple multinational pharmaceutical companies, innovative biotechnology companies, governmental and nongovernmental bodies including the Bill & Melinda Gates Foundation (BMGF), the Center for Epidemic Preparedness Innovations (CEPI), and the Biomedical Advanced Research and Development Authority (BARDA).
Alongside our strategic partner United Kingdom Health Security Agency (UKHSA) we developed reference vaccine and drug efficacy assessment assays and transferred this technology to a network of clinical testing laboratories all over the world. In fact, across the pandemic Nexelis has helped support more than 100 COVID-19-related development projects and testing tens of thousands of samples per month in our state-of-the-art BSL-2 and BSL-3 laboratory facilities.
The awards finalists are nominated and voted for by industry peers, with Scientific Advisory Board members acting as the judging panel to help make the final decision. The judging panel selected Nexelis as the winner based on criteria including the range of clinical laboratory/specialty laboratory services provided in support of vaccine development, how these services help successfully complete vaccines studies, as well as key milestones and outcomes that have led to our recognition as a central vaccine laboratory.
In January 2022, Nexelis joined Q² Solutions Company, a leading global clinical trial laboratory services organization providing bioanalytical, genomics, vaccines, flow cytometry, anatomic pathology, immunoassay, companion diagnostics and central laboratory services with secure, enterprise-wide biospecimen and consent management solutions.
